CG Oncology, Inc.
As of Oct 22, 2026, CG Oncology is in Stage 3, the topping phase, now in week 2 (since Oct 9, 2026). It closed at $62.54, 22.5% below its 52-week high and below its 200-day average, which is rising.
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is CGON early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
CGON among Biotechnology100th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …100 | CGON | Stage 3 · wk 2 | 84 | −14.7% |
CG Oncology: quick answers
What stage is CG Oncology in?
As of Oct 22, 2026, CG Oncology (CGON) is in Stage 3, the topping phase. It entered Stage 3 on Oct 9, 2026 and is in week 2. What the four stages mean
Is CG Oncology in an uptrend?
Its uptrend has stalled. CG Oncology is in Stage 3, the topping phase that follows an advance. It trades 4.5% below its 200-day average, which is rising.
How far is CG Oncology from its 52-week high?
CG Oncology closed at $62.54 on Oct 22, 2026, 22.5% below its 52-week high of $80.68. Its 52-week low is $37.37.
How has CG Oncology performed over the past year?
As of Oct 22, 2026, CG Oncology is up 45.2% over the past year and up 49.7% so far in 2026.
Which sector and industry is CG Oncology in?
CG Oncology is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Dallas, Texas.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.